Fig. 4

EZH2 inhibition alone and in combination with cisplatin reduces cell proliferation and increases cell death in HT1376 xenografts. a, b Representative H and E images showed no difference in tumor morphology between the different treatments. EZH2 expression was not altered between the treatment groups with a slight increase in combination-treated tumors; however, H3K27me3 levels were lower in the EPZ011989 and combination groups. Ki67, a proliferation marker, was reduced in EPZ011989 and combination groups compared to vehicle and cisplatin-treated tumors. TUNEL staining, an apoptosis marker was higher in all treatment groups compared with vehicle. Error bars represent standard error of means of all the mice in each group. One-way ANOVA model with pairwise comparisons made as appropriate were performed to test differences between single and combination treatments. *p < 0.05, **p < 0.01, ***p < 0.001, triangle indicates significant difference as compared to vehicle, hash indicates significant difference between the EPZ011989 and cisplatin alone treatments